Trial Profile
The analysis of day-to-day glucose excursions when switching from biphasic insulin 30 to insulin degludec and aspart
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Apr 2017
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary) ; Insulin degludec (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 17 Apr 2017 Status changed from recruiting to completed.
- 31 May 2016 New trial record